MIRA (36) QNRX (37) ATOS (33) CRVO (28) ⌘ Pro Terminal →

Immutep Limited (IMMP) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell IMMP stock right now?

Immutep Limited (IMMP) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

Q: What is IMMP's 12-month price target and RQD AI Jury consensus?

IMMP's 12-month base price target is $2.91 (range $2.27 to $67.83), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$3.06 -8.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.01

Immutep Limited (IMMP) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $22.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMMP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Immutep Limited (NASDAQ: IMMP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.06 (-8.11% 1D, market cap $22.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IMMP ranks #316 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMMP compare to MIRA and QNRX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMP carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MIRA (MIRA Pharmaceuticals Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $23.0M) and QNRX (Quoin Pharmaceuticals Ltd.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $21.8M). Among the 5-stock peer group, IMMP leads on earnings multiple (N/A) while MIRA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMMP?

▼

For Immutep Limited (IMMP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #316 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.01 (-1.65%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMMP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY IMMP SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($631.5K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$3.57-8.7% Next Q

Q2 (-2Q)

Grade C-$3.26-3.4% Next Q

Q3 (-1Q)

Grade C-$3.15-2.9% Next Q

Current

Grade D$3.06-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMMP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMMP currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.07) and Max Pain ($3.21) forces dealer call-delta covering toward $67.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMMP Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

29.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $2$3.06H: $65

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on IMMP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

12/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like IMMP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMMP)

✓Walkthrough of IMMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -66.74%▼ DESCENDING CHANNEL

2026-11-03O $3.33H $3.33L $3.06C $3.06VOL 10.6K

RES: $7.32SUP: $2.02SMA50: $5.07SMA200: $16.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMMP Butterfly Map → + Track IMMP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMMP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMMP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMMP)

Health Care Rank #316 of 1016 ⚔️ MIRA vs IMMP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMMP vs. MIRA, QNRX, ATOS, CRVO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Immutep Limited (IMMP) ranks #316 by composite RQD confidence (47/100, grade D) and #823 by equity capitalization ($22.6M). Within this direct 5-issuer industry benchmark cohort, IMMP leads on earnings valuation at N/A trailing P/E, while MIRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMMP ACTIVE Immutep Limited	D	47/100	—	—	—	-8.11%	$22.6M	Benchmark Subject
MIRA MIRA Pharmaceuticals Inc.	D-	36/100	—	—	-35.0%	-4.04%	$23.0M	/mira-vs-immp →
QNRX Quoin Pharmaceuticals Ltd.	D-	37/100	—	—	-35.0%	+9.40%	$21.8M	/qnrx-vs-immp →
ATOS Atossa Therapeutics Inc.	E	33/100	—	—	-35.0%	-2.69%	$21.7M	/atos-vs-immp →
CRVO CervoMed Inc.	E	28/100	—	—	-35.0%	-8.57%	$24.2M	/crvo-vs-immp →

2. IMMP Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Immutep Limited (IMMP) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $22.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IMMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IMMP compare to MIRA and QNRX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IMMP?

Where is IMMP trading relative to its 50-day, 200-day, and 52-week technical levels?

IMMP last traded at $3.06 (-8.11% on volume of 10,594 shares), positioning the stock -39.64% below its 50-day simple moving average ($5.07) and -81.33% below its 200-day simple moving average ($16.39). Across its 52-week range of $1.65 to $64.60, IMMP sits at the 2.2% percentile with a 14-day RSI of 29.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.68 to $3.44).

IMMP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IMMP stock right now?

Immutep Limited (IMMP) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is IMMP's 12-month price target and RQD AI Jury consensus?

IMMP's 12-month base price target is $2.91 (range $2.27 to $67.83), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IMMP RQD Cockpit IMMP 12M Forecast IMMP Earnings & Move IMMP Dividends & DRIP IMMP Insiders & 13F IMMP Whale Options IMMP Profit Sankey IMMP News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IMMP — Immutep Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:44Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IMMP scores 47 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The Fundamental Cash Engine pillar scores 12 of 20, with ROIC at 0% and FCF yield at 0%, indicating no reported return on invested capital or free-cash generation in the source data. The Whale 13F Flow pillar scores 3 of 20, the weakest pillar, reflecting institutional accumulation and options positioning. The Insider Conviction pillar scores 9 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 10 of 20, with Beta at 1.0 and sector sensitivity as cited. The Forensic Balance Sheet pillar scores 13 of 20, with Altman Z at 2.5, Piotroski F at 6/9, and Debt/Equity at 0.5, which is the relatively stronger pillar in the set. For a prospective investor, the rating signals limited upside drivers from cash generation and institutional sponsorship, a valuation that cannot be anchored to earnings or cash flow based on the available data, and a balance sheet that is comparatively sturdier than the other pillars suggest. The rating does not constitute personalized financial advice.

Recent Catalysts & News Wire Analysis

Listing status (YELLOW): Per Stock Titan, Nasdaq closed Immutep's listing case after 10 business days meeting the $1 bid minimum.
Clinical/scientific presentations (YELLOW): Per Yahoo Finance, a late-breaking abstract on IMP761 was accepted for poster presentation at ACR Convergence 2026. Per Yahoo Finance, quality-of-life data from the EFTISARC-NEO Phase II trial is slated for presentation at ESMO 2026.
Earnings loss (RED / RISK WATCH): Per Stock Titan, EPS 2025 was a $0.03 loss per share.
Capital structure (YELLOW): Per Kalkine Media, the FY2026 Annual Report reveals an ADS ratio increase to 200 shares.
General market wire (YELLOW): Per Yahoo! Finance Canada, a market report covers IMMP market action and positioning, without specific fundamental content.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's reported revenue, operating income, net income, cash, and debt figures, given that the financials section is empty?
What is the status and commercial pathway of IMP761 and the EFTISARC-NEO program referenced in the catalyst feed?
What is driving the 13F institutional flow and insider activity that produced the 3/20 and 9/20 pillar scores, given that holder data is absent?
What are the consensus analyst rating and price targets, given that analyst data is absent?
What caused the decline in price from a 52-week high of $64.6 to the current $3.33, and how does the ADS ratio change relate to that?

IMMP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Immutep Limited (IMMP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMMP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago

Immutep Limited (IMMP) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

Nasdaq closed Immutep's listing case after 10 business days meeting the $1 bid minimum.

Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

Immutep Limited (IMMP) EPS 2025: $0.03 loss per share

Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Immutep FY2026 Annual Report Reveals ADS Ratio Increase to 200 Shares

Kalkine Media report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Immutep Limited (IMMP) Total Assets 2025: $103.2M, down 23.3%

Stock Titan report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

Yahoo Finance report covering Immutep Limited (IMMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMMP Bull vs. Bear Conversation Board — What's Your Call at $3.06?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMMP 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.60 (+8.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IMMP (D • RQD 47/100) a Buy at $3.33?

Welcome to the IMMP (Immutep Limited) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.66 (-20.1%)

Spot @ $3.33

Pump the brakes on IMMP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IMMP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Immutep Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.26 (+27.9%)

Spot @ $3.33

IMMP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IMMP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.33 (52-wk range $1.65 - $64.60), any beat on forward guidance forces shorts and underweight funds to chase.